UCLA Electronic Theses and Dissertations

Total Page:16

File Type:pdf, Size:1020Kb

UCLA Electronic Theses and Dissertations UCLA UCLA Electronic Theses and Dissertations Title Analyses of Next-Generation Sequencing Data to Identify Genes Associated with Complex Neuropsychiatric Disorders Permalink https://escholarship.org/uc/item/64r0d41z Author Rao, Aliz Raksi Publication Date 2017 Supplemental Material https://escholarship.org/uc/item/64r0d41z#supplemental Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA Los Angeles Analyses of Next-Generation Sequencing Data to Identify Genes Associated with Complex Neuropsychiatric Disorders A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioinformatics by Aliz Raksi Rao 2017 © Copyright by Aliz Raksi Rao 2017 ABSTRACT OF THE DISSERTATION Analyses of Next-Generation Sequencing Data to Identify Genes Associated with Complex Neuropsychiatric Disorders by Aliz Raksi Rao Doctor of Philosophy in Bioinformatics University of California, Los Angeles, 2017 Professor Stanley F. Nelson, Chair Over the past decade, decreases in the cost of DNA sequencing has allowed for a surge in the amount of data being generated. This has led to the discovery of genes causal for hundreds of Mendelian disorders and genes associated with many complex disorders. Given the opportunity to use sequencing data to tackle neuropsychiatric diseases with a complex genetic architecture, I take a data-first approach to study two diseases, bipolar disorder and autism spectrum disorder (ASD). Combining information gleaned from next-gen sequencing (NGS) data with the latest analytic methods shines new light on the biology of these diseases. In the first part of this dissertation, I present a whole-exome analysis of nine affected individuals from four families in which bipolar disorder was transmitted over several generations, and six unrelated, affected individuals. Our results demonstrate the genetic heterogeneity of bipolar disorder and provide support for rare-variant oligogenic disease model. ii In the second part, I present an approach to identify rare variants associated with autism spectrum disorder (ASD) in a whole-genome sequencing study of 71 individuals diagnosed with ASD and their family members. I demonstrate that by incorporating knowledge of population- wide variant frequencies to analyses of NGS data and taking an approach sensitive to complex family structures, as opposed to utilizing only case-control or trio data, one can identify patterns that would otherwise have been missed and thus gain novel insights into disease etiology. Finally, I present a mutational burden dataset called SORVA (Significance Of Rare VAriants), which is useful in vetting candidate variants and genes from NGS studies. In effect, my studies of complex disorders using next-gen sequencing show the field is constantly evolving with new computational approaches allowing for many advances being made in the areas of psychiatric disorders and ASD, in particular. iii The dissertation of Aliz Raksi Rao is approved. Eleazar Eskin Janet S. Sinsheimer Rita M. Cantor Stanley F. Nelson, Committee Chair University of California, Los Angeles 2017 iv DEDICATION To my father, whose curiosity and enthusiasm for science I wholeheartedly share. Thank you for showing me the path and supporting me throughout this journey of discovery. To my spouse and partner, who has demonstrated incredible patience by supporting me along the way. “Success is the sum of small efforts— repeated day in and day out.” v TABLE OF CONTENTS Abstract of the Dissertation.............................................................................................................ii Signature Page................................................................................................................................iv Dedication........................................................................................................................................v Table of Contents............................................................................................................................vi List of Figures.................................................................................................................................ix List of Tables...................................................................................................................................x List of Acronyms............................................................................................................................xi Acknowledgements........................................................................................................................xii Vita................................................................................................................................................xiv 1 Introduction...................................................................................................................................1 1.1 Challenges of studying complex disorders via next-gen sequencing....................................1 1.2 Current methods to analyze large NGS datasets...................................................................2 1.3 The genetic basis of bipolar disorder....................................................................................4 1.4 The genetic basis of autism spectrum disorders....................................................................6 1.5 Bibliography..........................................................................................................................9 2 Rare deleterious mutations are associated with disease in bipolar disorder families.................20 2.1 Abstract...............................................................................................................................20 2.2 Introduction.........................................................................................................................21 2.3 Materials and Methods........................................................................................................23 2.3.1 Sample selection..........................................................................................................23 2.3.2 Exome sequencing and bioinformatics analysis..........................................................24 2.3.3 Variant annotation, filtering and interpretation...........................................................25 2.3.4 Statistical analysis.......................................................................................................25 2.4 Results.................................................................................................................................26 2.4.1 Sample characteristics.................................................................................................26 2.4.2 Identification of rare, damaging mutations.................................................................27 2.5 Discussion...........................................................................................................................30 2.6 Conclusions.........................................................................................................................33 vi 2.7 Supplementary Methods......................................................................................................34 2.7.1 Exome capture and re-sequencing...............................................................................34 2.7.2 Quality control (QC)....................................................................................................34 2.7.3 Sequence alignment and variant calling......................................................................35 2.7.4 Variant annotation, filtering and interpretation...........................................................36 2.8 Supplementary Tables.........................................................................................................38 2.9 Bibliography........................................................................................................................39 3 Whole-genome sequencing of web-based recruited individuals with autism spectrum disorders reveals novel candidate genes........................................................................................................45 3.1 Abstract...............................................................................................................................45 3.2 Introduction.........................................................................................................................46 3.3 Methods...............................................................................................................................47 3.3.1 Sample recruitment......................................................................................................47 3.3.2 Sequencing and bioinformatics pipeline.....................................................................49 3.3.3 Validation of de novo events.......................................................................................52 3.3.4 Functional Enrichment and Network Analyses...........................................................53 3.4 Results.................................................................................................................................53 3.5 Discussion...........................................................................................................................59
Recommended publications
  • Chr21 Protein-Protein Interactions: Enrichment in Products Involved in Intellectual Disabilities, Autism and Late Onset Alzheimer Disease
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.11.872606; this version posted December 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Chr21 protein-protein interactions: enrichment in products involved in intellectual disabilities, autism and Late Onset Alzheimer Disease Julia Viard1,2*, Yann Loe-Mie1*, Rachel Daudin1, Malik Khelfaoui1, Christine Plancon2, Anne Boland2, Francisco Tejedor3, Richard L. Huganir4, Eunjoon Kim5, Makoto Kinoshita6, Guofa Liu7, Volker Haucke8, Thomas Moncion9, Eugene Yu10, Valérie Hindie9, Henri Bléhaut11, Clotilde Mircher12, Yann Herault13,14,15,16,17, Jean-François Deleuze2, Jean- Christophe Rain9, Michel Simonneau1, 18, 19, 20** and Aude-Marie Lepagnol- Bestel1** 1 Centre Psychiatrie & Neurosciences, INSERM U894, 75014 Paris, France 2 Laboratoire de génomique fonctionnelle, CNG, CEA, Evry 3 Instituto de Neurociencias CSIC-UMH, Universidad Miguel Hernandez-Campus de San Juan 03550 San Juan (Alicante), Spain 4 Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA 5 Center for Synaptic Brain Dysfunctions, Institute for Basic Science, Daejeon 34141, Republic of Korea 6 Department of Molecular Biology, Division of Biological Science, Nagoya University Graduate School of Science, Furo, Chikusa, Nagoya, Japan 7 Department of Biological Sciences, University of Toledo, Toledo, OH, 43606, USA 8 Leibniz Forschungsinstitut für Molekulare Pharmakologie
    [Show full text]
  • Neural Stem Cell-Derived Exosomes Revert HFD-Dependent Memory Impairment Via CREB-BDNF Signalling
    International Journal of Molecular Sciences Article Neural Stem Cell-Derived Exosomes Revert HFD-Dependent Memory Impairment via CREB-BDNF Signalling Matteo Spinelli 1, Francesca Natale 1,2, Marco Rinaudo 1, Lucia Leone 1,2, Daniele Mezzogori 1, Salvatore Fusco 1,2,* and Claudio Grassi 1,2 1 Department of Neuroscience, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; [email protected] (M.S.); [email protected] (F.N.); [email protected] (M.R.); [email protected] (L.L.); [email protected] (D.M.); [email protected] (C.G.) 2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy * Correspondence: [email protected] Received: 6 October 2020; Accepted: 25 November 2020; Published: 26 November 2020 Abstract: Overnutrition and metabolic disorders impair cognitive functions through molecular mechanisms still poorly understood. In mice fed with a high fat diet (HFD) we analysed the expression of synaptic plasticity-related genes and the activation of cAMP response element-binding protein (CREB)-brain-derived neurotrophic factor (BDNF)-tropomyosin receptor kinase B (TrkB) signalling. We found that a HFD inhibited both CREB phosphorylation and the expression of a set of CREB target genes in the hippocampus. The intranasal administration of neural stem cell (NSC)-derived exosomes (exo-NSC) epigenetically restored the transcription of Bdnf, nNOS, Sirt1, Egr3, and RelA genes by inducing the recruitment of CREB on their regulatory sequences. Finally, exo-NSC administration rescued both BDNF signalling and memory in HFD mice. Collectively, our findings highlight novel mechanisms underlying HFD-related memory impairment and provide evidence of the potential therapeutic effect of exo-NSC against metabolic disease-related cognitive decline.
    [Show full text]
  • BDNF Integrity in Ageing and Stress
    MOJ Gerontology & Geriatrics Editorial Open Access BDNF integrity in ageing and stress Editorial Volume 1 Issue 6 - 2017 Alzheimer’s disease (AD) presents a progressive, stage-dependent Trevor Archer age-related neurodegenerative disorder that is characterized by Department of Psychology, University of Gothenburg, Sweden aggregation of toxic forms of amyloid β peptide (Aβ). There is much support for the notion that that brain-derived neurotrophic factor Correspondence: Trevor Archer, Department of Psychology, (BDNF) mediates beneficial effects of exercise on neuroplasticity and University of Gothenburg, Sweden, cellular stress resistance.1‒3 BDNF is associated with neuroplasticity Email [email protected] changes promoting health and well-being whereas these influences Received: July 16, 2017 | Published: August 01, 2017 may be opposed by pro-inflammatory cytokines, key factors in neurodegenerative processes.4 Lower serum levels are linked to greater symptom, cognitive, impairment.5 Thus, interventions, as for example physical exercise, whether acute or chronic, endurance or resistance, promote the mobilization of BDNF and other neurotrophic factors6,7 increase hippocampal and other brain regional resilience8 and therewith progression under conditions of stress when confronted critical life protect against cell death by inducing cell proliferation and maturation episodes or periods, appears to be modulated by the availability and with enhanced neuronal reparation, neurogenesis and the growth and accessibility of BDNF.20‒22 Over a wide range of neurologic and functioning of neurons in neurodegenerative disorders.9,10 Sampaio et psychiatric disease states it is found that the integrity and concentrations al.11 in a review of the therapeutic applications of neurotrophic factors, of brain, serum and plasma BDNF is compromised, particularly under particularly BDNF, postulate that they are essential for survival, stressful conditions.
    [Show full text]
  • Supplementary Table 8. Cpcp PPI Network Details for Significantly Changed Proteins, As Identified in 3.2, Underlying Each of the Five Functional Domains
    Supplementary Table 8. cPCP PPI network details for significantly changed proteins, as identified in 3.2, underlying each of the five functional domains. The network nodes represent each significant protein, followed by the list of interactors. Note that identifiers were converted to gene names to facilitate PPI database queries. Functional Domain Node Interactors Development and Park7 Rack1 differentiation Kcnma1 Atp6v1a Ywhae Ywhaz Pgls Hsd3b7 Development and Prdx6 Ncoa3 differentiation Pla2g4a Sufu Ncf2 Gstp1 Grin2b Ywhae Pgls Hsd3b7 Development and Atp1a2 Kcnma1 differentiation Vamp2 Development and Cntn1 Prnp differentiation Ywhaz Clstn1 Dlg4 App Ywhae Ywhab Development and Rac1 Pak1 differentiation Cdc42 Rhoa Dlg4 Ctnnb1 Mapk9 Mapk8 Pik3cb Sod1 Rrad Epb41l2 Nono Ltbp1 Evi5 Rbm39 Aplp2 Smurf2 Grin1 Grin2b Xiap Chn2 Cav1 Cybb Pgls Ywhae Development and Hbb-b1 Atp5b differentiation Hba Kcnma1 Got1 Aldoa Ywhaz Pgls Hsd3b4 Hsd3b7 Ywhae Development and Myh6 Mybpc3 differentiation Prkce Ywhae Development and Amph Capn2 differentiation Ap2a2 Dnm1 Dnm3 Dnm2 Atp6v1a Ywhab Development and Dnm3 Bin1 differentiation Amph Pacsin1 Grb2 Ywhae Bsn Development and Eef2 Ywhaz differentiation Rpgrip1l Atp6v1a Nphp1 Iqcb1 Ezh2 Ywhae Ywhab Pgls Hsd3b7 Hsd3b4 Development and Gnai1 Dlg4 differentiation Development and Gnao1 Dlg4 differentiation Vamp2 App Ywhae Ywhab Development and Psmd3 Rpgrip1l differentiation Psmd4 Hmga2 Development and Thy1 Syp differentiation Atp6v1a App Ywhae Ywhaz Ywhab Hsd3b7 Hsd3b4 Development and Tubb2a Ywhaz differentiation Nphp4
    [Show full text]
  • STAU2 (NM 001164380) Human Untagged Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC327098 STAU2 (NM_001164380) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: STAU2 (NM_001164380) Human Untagged Clone Tag: Tag Free Symbol: STAU2 Synonyms: 39K2; 39K3 Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 STAU2 (NM_001164380) Human Untagged Clone – SC327098 Fully Sequenced ORF: >NCBI ORF sequence for NM_001164380, the custom clone sequence may differ by one or more nucleotides ATGGCAAACCCAAAAGAGAAAACTGCAATGTGTCTGGTAAATGAGTTAGCCCGTTTCAATAGAGTCCAAC CCCAGTATAAACTTCTGAATGAAAGAGGGCCTGCTCATTCAAAGATGTTCTCAGTGCAGCTGAGTCTTGG TGAGCAGACATGGGAATCCGAAGGCAGCAGTATAAAGAAGGCTCAGCAGGCTGTTGCCAATAAAGCTTTG ACTGAATCTACGCTTCCCAAACCAGTTCAGAAGCCACCCAAAAGTAATGTTAACAATAACCCAGGCAGTA TAACTCCAACTGTGGAACTGAATGGGCTTGCTATGAAAAGGGGAGAGCCTGCCATCTACAGGCCATTAGA TCCAAAGCCATTCCCAAATTATAGAGCTAATTACAACTTTCGGGGCATGTACAATCAGAGGTATCATTGC CCAGTGCCTAAGATCTTTTATGTTCAGCTCACTGTAGGAAATAATGAATTTTTTGGGGAAGGAAAGACTC GACAAGCTGCTAGACACAATGCTGCAATGAAAGCCCTCCAAGCACTGCAGAATGAACCTATTCCAGAAAG ATCTCCTCAGAATGGTGAATCAGGAAAGGATGTGGATGATGACAAAGATGCAAATAAGTCTGAGATCAGC TTAGTGTTTGAAATTGCTCTGAAGCGAAATATGCCTGTCAGTTTTGAGGTTATTAAAGAAAGTGGACCAC
    [Show full text]
  • Anti-STAU2 Monoclonal Antibody, Clone 2D7 (DCABH-6925) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-STAU2 monoclonal antibody, clone 2D7 (DCABH-6925) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview Mouse monoclonal to STAU2 - C-terminal Antigen Description RNA-binding protein required for the microtubule-dependent transport of neuronal RNA from the cell body to the dendrite. As protein synthesis occurs within the dendrite, the localization of specific mRNAs to dendrites may be a prerequisite for neurite outgrowth and plasticity at sites distant from the cell body. Immunogen Synthetic peptide within Human STAU2 aa 379-570 (C terminal). The exact sequence is proprietary.Database link: Q9NUL3 Source/Host Mouse Species Reactivity Mouse, Rat, Human Clone 2D7 Conjugate Unconjugated Applications WB, ICC/IF Format Liquid Size 125 μl Buffer pH: 9.0; Purification elution buffer is: 0.1 M glycine-HCl, pH 2.7 + Neutralizing buffer: 1 M Tris- HCl Preservative None Storage Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Ship Shipped at 4°C. GENE INFORMATION Gene Name STAU2 staufen, RNA binding protein, homolog 2 (Drosophila) [ Homo sapiens ] 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Official Symbol STAU2 Synonyms STAU2; staufen, RNA binding protein, homolog 2 (Drosophila); staufen (Drosophila, RNA binding protein) homolog 2; double-stranded RNA-binding protein Staufen homolog 2; 39K2; staufen homolog 2; 39K3; MGC119606; DKFZp781K0371; Entrez Gene ID 27067 Protein Refseq NP_001157852 UniProt ID Q9NUL3 Chromosome Location 8q21.11 Function double-stranded RNA binding; 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.
    [Show full text]
  • LGI1–ADAM22–MAGUK Configures Transsynaptic Nanoalignment for Synaptic Transmission and Epilepsy Prevention
    LGI1–ADAM22–MAGUK configures transsynaptic nanoalignment for synaptic transmission and epilepsy prevention Yuko Fukataa,b,1, Xiumin Chenc,d,1, Satomi Chikenb,e, Yoko Hiranoa,f, Atsushi Yamagatag, Hiroki Inahashia, Makoto Sanboh, Hiromi Sanob,e, Teppei Gotoh, Masumi Hirabayashib,h, Hans-Christian Kornaui,j, Harald Prüssi,k, Atsushi Nambub,e, Shuya Fukail, Roger A. Nicollc,d,2, and Masaki Fukataa,b,2 aDivision of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Aichi 444-8787, Japan; bDepartment of Physiological Sciences, School of Life Science, SOKENDAI (The Graduate University for Advanced Studies), Aichi 444-8585, Japan; cDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158; dDepartment of Physiology, University of California, San Francisco, CA 94158; eDivision of System Neurophysiology, Department of System Neuroscience, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Aichi 444-8585, Japan; fDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan; gLaboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research, Kanagawa 230-0045, Japan; hCenter for Genetic Analysis of Behavior, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki 444-8787, Japan; iGerman Center for Neurodegenerative Diseases (DZNE), 10117 Berlin, Germany; jNeuroscience Research Center, Cluster NeuroCure, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; kDepartment of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; and lDepartment of Chemistry, Graduate School of Science, Kyoto University, 606-8502 Kyoto, Japan Contributed by Roger A. Nicoll, December 1, 2020 (sent for review October 29, 2020; reviewed by David S.
    [Show full text]
  • Quantitative Proteomics Reveals Significant Differences
    cells Article Quantitative Proteomics Reveals Significant Differences between Mouse Brain Formations in Expression of Proteins Involved in Neuronal Plasticity during Aging Dominika Drulis-Fajdasz 1,† , Kinga Gostomska-Pampuch 2,3,† , Przemysław Duda 1 , Jacek Roman Wi´sniewski 2 and Dariusz Rakus 1,* 1 Department of Molecular Physiology and Neurobiology, University of Wrocław, Sienkiewicza 21, 50-335 Wrocław, Poland; [email protected] (D.D.-F.); [email protected] (P.D.) 2 Biochemical Proteomics Group, Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany; [email protected] (K.G.-P.); [email protected] (J.R.W.) 3 Department of Biochemistry and Immunochemistry, Wrocław Medical University, Chałubi´nskiego10, 50-368 Wrocław, Poland * Correspondence: [email protected] † The authors participated equally. Abstract: Aging is associated with a general decline in cognitive functions, which appears to be due to alterations in the amounts of proteins involved in the regulation of synaptic plasticity. Here, we present a quantitative analysis of proteins involved in neurotransmission in three brain regions, namely, the hippocampus, the cerebral cortex and the cerebellum, in mice aged 1 and 22 months, Citation: Drulis-Fajdasz, D.; using the total protein approach technique. We demonstrate that although the titer of some proteins Gostomska-Pampuch, K.; Duda, P.; involved in neurotransmission and synaptic plasticity is affected by aging in a similar manner Wi´sniewski,J.R.; Rakus, D. Quantitative Proteomics Reveals in all the studied brain formations, in fact, each of the formations represents its own mode of Significant Differences between aging.
    [Show full text]
  • Novel Extensions of Label Propagation for Biomarker Discovery in Genomic Data
    NOVEL EXTENSIONS OF LABEL PROPAGATION FOR BIOMARKER DISCOVERY IN GENOMIC DATA by Matthew E. Stokes B.S. Systems and Control Engineering, Case Western Reserve University, 2008 M.S. Intelligent Systems Program / Biomedical Informatics, University of Pittsburgh 2011 Submitted to the Graduate Faculty of the Kenneth P. Dietrich School of Arts and Sciences in fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2014 UNIVERSITY OF PITTSBURGH DIETRICH SCHOOL OF ARTS AND SCIENCES This dissertation proposal was presented by Matthew E. Stokes on July 17, 2014 and approved by M. Michael Barmada, PhD, Department of Human Genetics Gregory F. Cooper, MD, PhD, Department of Biomedical Informatics and the Intelligent Systems Program Milos Hauskrecht, PhD, Department of Computer Science and the Intelligent Systems Program Dissertation Advisor: Shyam Visweswaran, MD, PhD, Department of Biomedical Informatics and the Intelligent Systems Program ii NOVEL EXTENSIONS OF LABEL PORPAGATION FOR BIOMARKER DISCOVERY IN GENOMIC DATA Matthew E. Stokes, M.S University of Pittsburgh, 2014 Copyright © by Matthew E. Stokes 2014 iii NOVEL EXTENSIONS OF LABEL PROPAGATION FOR BIOMARKER DISCOVERY IN GENOMIC DATA Matthew E. Stokes, PhD University of Pittsburgh, 2014 One primary goal of analyzing genomic data is the identification of biomarkers which may be causative of, correlated with, or otherwise biologically relevant to disease phenotypes. In this work, I implement and extend a multivariate feature ranking algorithm called label propagation (LP) for biomarker discovery in genome-wide single-nucleotide polymorphism (SNP) data. This graph-based algorithm utilizes an iterative propagation method to efficiently compute the strength of association between a SNP and a phenotype.
    [Show full text]
  • Dlg1 Maintains Dendritic Cell Function by Securing Voltage-Gated K+ Channel Integrity
    Dlg1 Maintains Dendritic Cell Function by Securing Voltage-Gated K + Channel Integrity This information is current as Xuejiao Dong, Lisi Wei, Xueheng Guo, Zhiyong Yang, of September 24, 2021. Chuan Wu, Peiyu Li, Lu Lu, Hai Qi, Yan Shi, Xiaoyu Hu, Li Wu, Liangyi Chen and Wanli Liu J Immunol published online 26 April 2019 http://www.jimmunol.org/content/early/2019/04/25/jimmun ol.1900089 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2019/04/25/jimmunol.190008 Material 9.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published April 26, 2019, doi:10.4049/jimmunol.1900089 The Journal of Immunology Dlg1 Maintains Dendritic Cell Function by Securing Voltage-Gated K+ Channel Integrity Xuejiao Dong,*,1 Lisi Wei,†,1 Xueheng Guo,‡,x,1 Zhiyong Yang,{ Chuan Wu,‖ Peiyu Li,#,** Lu Lu,# Hai Qi,‡ Yan Shi,‡ Xiaoyu Hu,‡ Li Wu,‡ Liangyi Chen,† and Wanli Liu* Dendritic cells (DCs) play key roles in Ab responses by presenting Ags to lymphocytes and by producing proinflammatory cytokines.
    [Show full text]
  • BMC Biology Biomed Central
    BMC Biology BioMed Central Research article Open Access Classification and nomenclature of all human homeobox genes PeterWHHolland*†1, H Anne F Booth†1 and Elspeth A Bruford2 Address: 1Department of Zoology, University of Oxford, South Parks Road, Oxford, OX1 3PS, UK and 2HUGO Gene Nomenclature Committee, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK Email: Peter WH Holland* - [email protected]; H Anne F Booth - [email protected]; Elspeth A Bruford - [email protected] * Corresponding author †Equal contributors Published: 26 October 2007 Received: 30 March 2007 Accepted: 26 October 2007 BMC Biology 2007, 5:47 doi:10.1186/1741-7007-5-47 This article is available from: http://www.biomedcentral.com/1741-7007/5/47 © 2007 Holland et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The homeobox genes are a large and diverse group of genes, many of which play important roles in the embryonic development of animals. Increasingly, homeobox genes are being compared between genomes in an attempt to understand the evolution of animal development. Despite their importance, the full diversity of human homeobox genes has not previously been described. Results: We have identified all homeobox genes and pseudogenes in the euchromatic regions of the human genome, finding many unannotated, incorrectly annotated, unnamed, misnamed or misclassified genes and pseudogenes.
    [Show full text]
  • Hypoxia Transcriptomic Modifications Induced by Proton Irradiation In
    Journal of Personalized Medicine Article Hypoxia Transcriptomic Modifications Induced by Proton Irradiation in U87 Glioblastoma Multiforme Cell Line Valentina Bravatà 1,2,† , Walter Tinganelli 3,†, Francesco P. Cammarata 1,2,* , Luigi Minafra 1,2,* , Marco Calvaruso 1,2 , Olga Sokol 3 , Giada Petringa 2, Giuseppe A.P. Cirrone 2, Emanuele Scifoni 4 , Giusi I. Forte 1,2,‡ and Giorgio Russo 1,2,‡ 1 Institute of Molecular Bioimaging and Physiology–National Research Council (IBFM-CNR), 90015 Cefalù, Italy; [email protected] (V.B.); [email protected] (M.C.); [email protected] (G.I.F.); [email protected] (G.R.) 2 Laboratori Nazionali del SUD, Istituto Nazionale di Fisica Nucleare (LNS-INFN), 95100 Catania, Italy; [email protected] (G.P.); [email protected] (G.A.P.C.) 3 Biophysics Department, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany; [email protected] (W.T.); [email protected] (O.S.) 4 Trento Institute for Fundamental Physics and Applications (TIFPA), Istituto Nazionale Fisica Nucleare (INFN), 38123 Trento, Italy; [email protected] * Correspondence: [email protected] (F.P.C.); [email protected] (L.M.) † These authors contributed equally to this work. ‡ These authors contributed equally to this work. Abstract: In Glioblastoma Multiforme (GBM), hypoxia is associated with radioresistance and poor prognosis. Since standard GBM treatments are not always effective, new strategies are needed Citation: Bravatà, V.; Tinganelli, W.; to overcome resistance to therapeutic treatments, including radiotherapy (RT). Our study aims Cammarata, F.P.; Minafra, L.; to shed light on the biomarker network involved in a hypoxic (0.2% oxygen) GBM cell line that Calvaruso, M.; Sokol, O.; Petringa, G.; is radioresistant after proton therapy (PT).
    [Show full text]